Skip to main content

Pioneering microbiome diagnostics to transform cancer care

Immune checkpoint inhibitor response prediction test

Stool donor identification for non-responders

Explorative microbiome analysis

BiomeOne®– ICI response prediction

CE-IVD marked

BiomeOne® is the world’s first stool-based response prediction test for immunotherapy (ICI). With BiomeOne® we are able to analyze the patient’s unique intestinal microbiome signature and provide a single biomarker that informs the oncologist’s treatment decision on whether or not cancer immunotherapy benefits the patient.

Predicts response & tolerability to cancer immunotherapy
Supports decision making at the point of care
Non-invasive & performed on a single stool sample

More information

Microbiome diagnostics is certainly one of the most promising research areas of our time. This project should provide us with deeper insights into the interaction between the body's own microbiome and cancer immunotherapy. This could help us in the future to tailor cancer treatment more specifically to affected patients and to individualize the risk-benefit profile of the therapy as much as possible.

Prim. Doz. Dr. Arschang ValipourHead of Karl Landsteiner Institute for Lung Research and Pulmonary Oncology, Austria

81 %

Prediction sensitivity


Patient samples included


A.I. optimization cycles
Risk-benefit analysis
Identification of therapy response
Evaluation of adverse events

Receive valid results from a single sample

Only one stool sample is required to perform a thorough DNA analysis and predict the probability of response to cancer immunotherapy for an individual patient.

Currently, BiomeOne® has a prediction accuracy of >80% based on samples from cancer patients across middle Europe and the US.

Created with

BiomeOne® delivers consistent results for PD-1/PDL-1 and CTLA-4 inhibitors

BiomeOne® is based on extensive in-house research and results from multiple international studies in which patients received PD-1/PDL-1 as well as CTLA-4 inhibitors. The effect has proven to be pathway independent.

It took over thousands of different variations of machine learning algorithms to identify the best suited methods to analyse the response and tolerability prediction to immune checkpoint inhibitors.

Reliable and consistent across three different types of cancer

BiomeOne® is based on robust data from non-small-cell lung cancer, renal cell carcinoma and malignant melanoma patients. Our biomarker has proven to deliver reliable and consistent results across all three cancer types.

Comparison with other cancer types strongly suggest that the immune modulating effect of the intestinal microbiome is systemic and therefore not limited to a specific disease, but rather tumor agnostic.

Non-small-cell lung cancer
Malignant melanoma
Renal cell carcinoma

Step-by-step BiomeOne®


Oncologist places order via BiomeDx Platform


Patient receives stool kit, takes sample and ships sample to our laboratory


We perform DNA sequencing and calculate response parameters


Oncologist receives comprehensive report to support the individual treatment decision

Access the BiomeDx Platform

BiomeCRC®– Early detection microbiome test for colorectal cancer

Available 2022

BiomeCRC is a colorectal cancer preventive screening test based on the intestinal microbiome. The tool is powered by the proven BiomeDx platform and data from numerous clinical trials. Ongoing research in collaboration with the Medical University of Vienna includes over 1000 probands.

Product features

Cost efficient & non invasive
Able to differentiate tumour stages
Easily scaleable via screening programs

BiomeFMT – Stool donor identification for non-responders to cancer immunotherapy

Available 2023

BiomeFMT is a novel stool sample test – in development. BiomeFMT will be used to identify ideal donors for fecal microbiota transplantation for non-responders to cancer immunotherapy (ICI). For the first time it will be possible to screen large amounts of samples from biobanks in order to find potential super-responders to ICI.

Product features

Identifies donors for fecal microbiota transplantation
Unlock the full power of cancer immunotherapy
Scalable for broad clinical use

myBioma®– Because your health starts in the gut

Available on

Our well-established lifestyle product myBioma® is available for any European citizen to analyse one’s gut health. The microbiome report is available via PDF and mobile app on iOS and Android. The results include information on diversity, nutrition, health and dietary recommendations as well as a large network of therapists.

More information about myBioma® can be found at

Partner solution – End-to-end solution for microbiome analysis

Clinical trials, pilot projects, discovery

As a research-driven company, we collaborate with academic institutions and partners to uncover new correlations in the microbiome. For this purpose, we have developed an own study pipeline that performs statistical and machine learning algorithms in regards to the main hypothesis of the project.

Quality of a clinical study or related project is of the highest priority to us. We are the only and worldwide first microbiome company to be ISO certified according to 13485 (medical products) and 9001 (quality management).

Are you interested in our products or want to find out more on our pipeline?
We are glad to give you deeper insights.

Contact us